C4 Therapeutics, Inc. Financing Cash Flow
C4 Therapeutics, Inc. (CCCC) reported Financing Cash Flow of $34.19 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-11
- C4 Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $33.73M.
- C4 Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $462.00K.
- C4 Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $118.67M, a 105857.14% increase year-over-year.
- C4 Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $7.77M, a 26.01% decline year-over-year.
- C4 Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $126.40M, a 178.80% increase from fiscal 2024.
- C4 Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $45.34M, a 0.34% decline from fiscal 2023.
- C4 Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $45.49M, a 3865.91% increase from fiscal 2022.
- C4 Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $1.15M, a 99.33% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $33.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $34.19M 10-Q · filed 2026-08-11 | $152.86M derived: sum of 3 quarters · filed 2026-08-11 | $160.63M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $462.00K 10-Q · filed 2026-05-12 | $119.13M derived: sum of 2 quarters · filed 2026-05-12 | $126.91M derived: sum of 3 quarters · filed 2026-05-12 | $126.91M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $118.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $126.44M derived: sum of 2 quarters · filed 2026-02-26 | $126.44M derived: sum of 3 quarters · filed 2026-08-11 | $126.40M 10-K · filed 2026-02-26 |
| 2025-09-30 | $7.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $7.77M derived: sum of 2 quarters · filed 2026-08-11 | $7.73M 10-Q · filed 2025-11-06 | $7.84M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$46.00K 10-Q · filed 2026-08-11 | $66.00K derived: sum of 3 quarters · filed 2026-08-11 | $10.57M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$46.00K 10-Q · filed 2026-05-12 | $66.00K derived: sum of 2 quarters · filed 2026-05-12 | $10.57M derived: sum of 3 quarters · filed 2026-05-12 | $10.71M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $112.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $10.62M derived: sum of 2 quarters · filed 2026-02-26 | $10.75M derived: sum of 3 quarters · filed 2026-02-26 | $45.34M 10-K · filed 2026-02-26 |
| 2024-09-30 | $10.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $10.64M derived: sum of 2 quarters · filed 2025-11-06 | $45.22M 10-Q · filed 2025-11-06 | $102.90M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $135.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $34.72M 10-Q · filed 2025-08-07 | $92.39M derived: sum of 3 quarters · filed 2025-08-07 | $81.64M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $34.58M 10-Q · filed 2025-05-07 | $92.25M derived: sum of 2 quarters · filed 2025-05-07 | $81.50M derived: sum of 3 quarters · filed 2025-05-07 | $80.76M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $57.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $46.92M derived: sum of 2 quarters · filed 2025-02-27 | $46.17M derived: sum of 3 quarters · filed 2025-02-27 | $45.49M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$10.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$11.50M derived: sum of 2 quarters · filed 2024-10-31 | -$12.18M 10-Q · filed 2024-10-31 | -$12.14M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | -$746.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$1.43M 10-Q · filed 2024-08-01 | -$1.38M derived: sum of 3 quarters · filed 2024-08-01 | -$1.02M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | -$684.00K 10-Q · filed 2024-05-08 | -$637.00K derived: sum of 2 quarters · filed 2024-05-08 | -$276.00K derived: sum of 3 quarters · filed 2024-05-08 | -$17.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $47.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $408.00K derived: sum of 2 quarters · filed 2024-02-22 | $667.00K derived: sum of 3 quarters · filed 2024-02-22 | $1.15M 10-K · filed 2024-02-22 |
| 2022-09-30 | $361.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $620.00K derived: sum of 2 quarters · filed 2023-11-01 | $1.10M 10-Q · filed 2023-11-01 | $1.57M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | $259.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $739.00K 10-Q · filed 2023-08-08 | $1.21M derived: sum of 3 quarters · filed 2023-08-08 | $1.79M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $480.00K 10-Q · filed 2023-05-04 | $946.00K derived: sum of 2 quarters · filed 2023-05-04 | $1.53M derived: sum of 3 quarters · filed 2023-05-04 | $172.03M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $466.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $1.05M derived: sum of 2 quarters · filed 2023-02-23 | $171.55M derived: sum of 3 quarters · filed 2023-02-23 | $171.40M 10-K · filed 2023-02-23 |
| 2021-09-30 | $584.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $171.09M derived: sum of 2 quarters · filed 2022-11-03 | $170.93M 10-Q · filed 2022-11-03 | $364.99M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $170.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $170.35M 10-Q · filed 2022-08-04 | $364.40M derived: sum of 3 quarters · filed 2022-08-04 | $366.90M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$151.00K 10-Q · filed 2022-05-05 | $193.90M derived: sum of 2 quarters · filed 2022-05-05 | $196.40M derived: sum of 3 quarters · filed 2022-05-05 | $348.63M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $194.05M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $196.55M derived: sum of 2 quarters · filed 2022-02-24 | $348.78M derived: sum of 3 quarters · filed 2022-02-24 | $348.93M 10-K · filed 2022-02-24 |
| 2020-09-30 | $2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $154.72M derived: sum of 2 quarters · filed 2021-11-10 | $154.88M 10-Q · filed 2021-11-10 | $154.96M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $152.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $152.38M 10-Q · filed 2021-08-11 | $152.46M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2020-03-31 | $156.00K 10-Q · filed 2021-05-13 | $234.00K derived: sum of 2 quarters · filed 2022-02-24 | ||
| 2019-12-31 | $78.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $244.00K 10-K · filed 2022-02-24 | ||
| 2019-09-30 | $166.00K 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |